Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Abstract A101: Codon-specific KRAS mutations predict survival in advanced pancreatic cancer

Alice Boilève, Adrien Rousseau, Marc Hilmi, Anthony Tarabay, Jacques R.R. Mathieu, Negaar Goudarzi, Jérôme Cartry, Sabrina Bedja, Claudio Nicotra, Maud NgoCamus, Valérie Boige, Marine Valéry, Mohamed Amine Bani, Lambros Tselikas, Antoine Italiano, Fanny Jaulin, Cristina Smolenschi, Antoine Hollebecque, Michel Ducreux

Cancer Res (2024) 84 (2_Supplement): A101.

https://doi.org/10.1158/1538-7445.PANCA2023-A101

Published: 16 January 2024

View article titled, Abstract A101: Codon-specific KRAS mutations predict survival in advanced pancreatic cancer

Journal Articles

Abstract CT153: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors

Olivia Le Saux, Antoine Italiano, Dominique Spaeth, Pierre Heudel, Thomas Filleron, Laurence Albiges, Thomas Bachelot, Anthony Gonçalves, Jean-Yves Pierga, Fabrice Barlesi, Valérie Boige, Céleste Lebbé, Laurent Mortier, Jean Sébastien Frenel, Olivier Tredan, Marta Jimenez, François Legrand, Charles Ferte

Cancer Res (2018) 78 (13_Supplement): CT153.

https://doi.org/10.1158/1538-7445.AM2018-CT153

Published: 01 July 2018

View article titled, Abstract CT153: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors

Journal Articles

Abstract 603: Consensus molecular subtyping through a community of experts advances unsupervised gene expression-based disease classification and facilitates clinical translation

Cancer Res (2015) 75 (15_Supplement): 603.

https://doi.org/10.1158/1538-7445.AM2015-603

Published: 01 August 2015

View article titled, Abstract 603: Consensus molecular subtyping through a community of experts advances unsupervised gene expression-based disease classification and facilitates clinical translation

Journal Articles

Abstract 2820: Clinical significance of low frequency KRAS and BRAF subclones for advanced colon cancer management

Valerie Taly, Pierre Laurent-puig, Deniz Pekin, Corinne Normand, Steve K. Kotsopoulos, Philippe Nizard, Jeff Olson, Preethi Srinivasan, Delphine L. Corre, Xinyu Li, Qun Zhong, Darren R. Link, Olivier Bouché, Jean-François Emile, Bruno Landi, Valérie Boige, Brian J. Hutchison

Cancer Res (2014) 74 (19_Supplement): 2820.

https://doi.org/10.1158/1538-7445.AM2014-2820

Published: 01 October 2014

View article titled, Abstract 2820: Clinical significance of low frequency KRAS and BRAF subclones for advanced colon cancer management

Journal Articles

Abstract 474: Tumor CD57+ immune cell infiltration is a strong independent prognostic factor in stage II-III colorectal cancer

Valerie Boige, Clara Locher, Magali Svreck, Anne Auperin, Nathalie Chaput

Cancer Res (2011) 71 (8_Supplement): 474.

https://doi.org/10.1158/1538-7445.AM2011-474

Published: 15 April 2011

View article titled, Abstract 474: Tumor CD57+ immune cell infiltration is a strong independent prognostic factor in stage II-III colorectal cancer

Journal Articles

Abstract 4154: Intratumoral heterogeneity of HER2/neu expression in diffuse-gastric carcinoma of European patients and its relevance for patients’ management

Gorana Tomasic, Gabriel G. Malouf, Virginie Marty, David Malka, Philippe Vielh, Michel Ducreux, Valerie Boige

Cancer Res (2010) 70 (8_Supplement): 4154.

https://doi.org/10.1158/1538-7445.AM10-4154

Published: 15 April 2010

View article titled, Abstract 4154: Intratumoral heterogeneity of HER2/neu expression in diffuse-gastric carcinoma of European patients and its relevance for patients’ management

Journal Articles

Abstract 373: Circulating endothelial cell measurement allows early prediction of outcome in patients with metastatic colorectal cancer treated with first-line bevacizumab and chemotherapy. Findings from the FNCLCC ACCORD 13/0503 randomized phase II trial

Valerie Boige, Jean Mendiboure, Antoine Adenis, Evelyne Boucher, Jean-Yves Pierga, Eric Francois, Thierry Conroy, Jean-Pierre Pignon, Michel Ducreux, Françoise Farace, David Malka

Cancer Res (2010) 70 (8_Supplement): 373.

https://doi.org/10.1158/1538-7445.AM10-373

Published: 15 April 2010

View article titled, Abstract 373: Circulating endothelial cell measurement allows early prediction of outcome in patients with metastatic colorectal cancer treated with first-line bevacizumab and chemotherapy. Findings from the FNCLCC ACCORD 13/0503 randomized phase II trial

Journal Articles

Abstract 2306: The prognostic impact of epithelial mesenchymal transition markers in primary diffuse gastric carcinoma and their relative lymph nodes

Gabriel G. Malouf, Gorana Tomasic, Virginie Marty, David Malka, Philippe Vielh, Michel Ducreux, Valerie Boige

Cancer Res (2010) 70 (8_Supplement): 2306.

https://doi.org/10.1158/1538-7445.AM10-2306

Published: 15 April 2010

View article titled, Abstract 2306: The prognostic impact of epithelial mesenchymal transition markers in primary diffuse gastric carcinoma and their relative lymph nodes

Journal Articles

Abstract #1897: Analysis of PTEN, BRAF and EGFR status in determining benefit from cetuximab therapy in patients with metastatic colon cancer in wild-type KRAS patients

Pierre Laurent-Puig, Anne Cayre, Gilles Manceau, Denis Pezet, Jean-baptiste Bachet, Lecomte Thierry, Frederic Bibeau, Valerie Boige, Olivier Bouché, Julia Reid, Steven Stone, Fredrique Penault-Llorca

Cancer Res (2009) 69 (9_Supplement): 1897.

Published: 01 May 2009

View article titled, Abstract #1897: Analysis of PTEN, BRAF and EGFR status in determining benefit from cetuximab therapy in patients with metastatic colon cancer in wild-type KRAS patients

Journal Articles

Abstract #5402: Circulating endothelial cells (CEC) and angiogenic proteins monitoring in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with bevacizumab

Valerie Boige, Cecile Lafoix, Sarah Horn, Jean-Pierre Pignon, Clarisse Dromain, Farace Françoise

Cancer Res (2009) 69 (9_Supplement): 5402.

Published: 01 May 2009

View article titled, Abstract #5402: Circulating endothelial cells (CEC) and angiogenic proteins monitoring in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with bevacizumab

Journal Articles

Pharmacogenetic analysis in patients with advanced colorectal cancer treated with LV5FU2, FOLFOX and FOLFIRI: Results from a randomized trial of treatment strategy (FFCD 2000-05)

Valerie Boige, Marine Castaing, Marie-Anne Loriot, Michel Barrois, Delphine Lecorre, Isabelle Miran, Claire Mulot, Jean-Pierre Pignon, Michel Ducreux, Pierre Laurent-Puig

Cancer Res (2008) 68 (9_Supplement): 218.

Published: 01 May 2008

View article titled, Pharmacogenetic analysis in patients with advanced colorectal cancer treated with LV5FU2, FOLFOX and FOLFIRI: Results from a randomized trial of treatment strategy (FFCD 2000-05)

Journal Articles

Differential expression of molecular markers in intestinal and diffuse types of gastric carcinomas (GCA)

Ghassan El Maalouf, Marc Poccard, Jean-Charles Sabourin, Dominique Elias, David Malka, Michel Ducreux, Valerie Boige

Cancer Res (2008) 68 (9_Supplement): 2198.

Published: 01 May 2008

View article titled, Differential expression of molecular markers in intestinal and diffuse types of gastric carcinomas (GCA)

Journal Articles

KRAS mutations in colorectal cancer is a predictive factor of response and progression free survival in patients treated with Cetuximab.

Astrid Lievre, Jean-Baptiste Bachet, Marc Ychou, Olivier Bouche, Denis Pezet, Valerie Boige, Bruno Landi, Christophe Louvet, Jean-Francois Emile, Frederic Bibeau, Marie-Danielle Diebold, Gorana Tomasic, Jean-Francois Cote, Jean-Francois Flejou, Philippe Rougier, Frederic Penault-Llorca, Pierre Laurent-Puig

Cancer Res (2007) 67 (9_Supplement): 5671.

Published: 01 May 2007

View article titled, KRAS mutations in colorectal cancer is a predictive factor of response and progression free survival in patients treated with Cetuximab.

Journal Articles

Genome-wide expression profiling for prediction of recurrences in stage II-III colon adenocarcinoma: Cautions and proposals from a preliminary experience.

Valerie Boige, Stefan Michiels, Philippe Dessen, Jean-Christophe Sabourin, Marc Pocard, Michel Ducreux, Vladimir Lazar

Cancer Res (2005) 65 (9_Supplement): 21.

Published: 01 May 2005

View article titled, Genome-wide expression profiling for prediction of recurrences in stage II-III colon adenocarcinoma: Cautions and proposals from a preliminary experience.

Journal Articles

Concerted Nonsyntenic Allelic Losses in Hyperploid Hepatocellular Carcinoma as Determined by a High-Resolution Allelotype

Valérie Boige, Pierre Laurent-Puig, Pierre Fouchet, Jean François Fléjou, Geneviève Monges, Pierre Bedossa, Paulette Bioulac-Sage, Frédérique Capron, Anette Schmitz, Sylviane Olschwang, Gilles Thomas

Cancer Res (1997) 57 (10): 1986–1990.

Published: 01 May 1997

View article titled, Concerted Nonsyntenic Allelic Losses in Hyperploid Hepatocellular Carcinoma as Determined by a High-Resolution Allelotype

NARROW

Abstract A101: Codon-specific KRAS mutations predict survival in advanced pancreatic cancer

Abstract CT153: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors

Abstract 603: Consensus molecular subtyping through a community of experts advances unsupervised gene expression-based disease classification and facilitates clinical translation

Abstract 2820: Clinical significance of low frequency KRAS and BRAF subclones for advanced colon cancer management

Abstract 474: Tumor CD57+ immune cell infiltration is a strong independent prognostic factor in stage II-III colorectal cancer

Abstract 4154: Intratumoral heterogeneity of HER2/neu expression in diffuse-gastric carcinoma of European patients and its relevance for patients’ management

Abstract 373: Circulating endothelial cell measurement allows early prediction of outcome in patients with metastatic colorectal cancer treated with first-line bevacizumab and chemotherapy. Findings from the FNCLCC ACCORD 13/0503 randomized phase II trial

Abstract 2306: The prognostic impact of epithelial mesenchymal transition markers in primary diffuse gastric carcinoma and their relative lymph nodes

Abstract #1897: Analysis of PTEN, BRAF and EGFR status in determining benefit from cetuximab therapy in patients with metastatic colon cancer in wild-type KRAS patients

Abstract #5402: Circulating endothelial cells (CEC) and angiogenic proteins monitoring in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with bevacizumab

Pharmacogenetic analysis in patients with advanced colorectal cancer treated with LV5FU2, FOLFOX and FOLFIRI: Results from a randomized trial of treatment strategy (FFCD 2000-05)

Differential expression of molecular markers in intestinal and diffuse types of gastric carcinomas (GCA)

KRAS mutations in colorectal cancer is a predictive factor of response and progression free survival in patients treated with Cetuximab.

Genome-wide expression profiling for prediction of recurrences in stage II-III colon adenocarcinoma: Cautions and proposals from a preliminary experience.

Concerted Nonsyntenic Allelic Losses in Hyperploid Hepatocellular Carcinoma as Determined by a High-Resolution Allelotype

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only